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Subclinical hypothyroidism (SCH), defined by a normal total or free T4 level and a mildly elevated TSH (typically 5–10mU/L), is
common in children, but there is currently no consensus onmanagement. Several recent pediatric studies indicate that progression
of SCH to overt hypothyroidism (OH) is uncommon and that over a period of several years, elevated TSH usually either normalizes
or persists but does not increase. The etiology appears to be multifactorial, with some cases representing minor developmental
abnormalities, some related to obesity, some to mild autoimmune thyroiditis, and some associated with mutations in the gene
for the TSH-receptor. There are no pediatric studies showing clinical benefit of treating these children with thyroid hormone,
but additional studies in this area are needed. Since few cases of pediatric SCH progress to OH, treatment can be deferred, and
periodic follow-up testing may be the preferred strategy, with elevated thyroid antibodies or a goiter being considered risk factors
for eventual OH.
1. Introduction
Primary care physicians and pediatric endocrinologists fre-
quently face the decision of what to do about the child who
has a normal total or free T4 level and a slightly elevated
TSH (typically 5–10mU/L), a situation usually referred to
as subclinical hypothyroidism (SCH) [1]. The reasons for
ordering the tests in the first place vary, but many primary
care physicians believe that prompt evaluation and treatment
are essential. The response of pediatric endocrinologists may
range from a decision to start thyroid hormone immediately
after confirmation of the elevated TSH, to recommending
frequent monitoring of TSH for prolonged periods, to the
suggestion that unless a follow-up test shows a further
significant rise in TSH or a subnormal free T4, no action
should be taken.
There are several reasons for this lack of consensus
among pediatric endocrinologists. First, there have been
until recently a scarcity of studies reporting on the natural
history of SCH in children; thus there has been concern that
if untreated, SCH will frequently progress to overt hypothy-
roidism (OH). OH will be defined here as a low total or free
T4 with a TSH of >20mU/L, which all clinicians would agree
requires treatment, though occasionally one encounters a
clearly low free T4 with a TSH in the 10–20mU/L range.
There are no controlled pediatric studies (as there are in
adults) looking at outcomes of children with SCH treated
with l-thyroxine versus those given placebo. Furthermore,
there is a high risk of developmental delay in infants who
have untreated severe congenital hypothyroidism (low T4
and TSH usually >100). Since many children with SCH are
identified during newborn screening or during the first year
of life, physicians may be concerned that failing to treat SCH
will expose the child to the risk of developmental delay if OH
develops later or that treatment is needed to prevent growth
retardation [1].
The cost implications of the decision to treat or not to
treat an individual child with thyroid hormone may seem
small, considering that thyroid hormone costs only $100–
$200 per year depending on whether one uses generic l-
thyroxine or a brand. However, the decision to treat a
child with SCH long term may involve a lifetime of thyroid
hormone replacement and frequent monitoring of total or
free T4 and TSH levels. At a widely used commercial lab, the
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cost of a free T4 is $144, and the TSH test costs $170; during
the first years of life, it is typical for tests to be repeated every
few months, with less frequent but at least annual testing as
the child gets older.
This paper will summarize what we know about the
natural history of SCH in children and will explore some of
the etiologies for both transient and persistent mild elevation
of TSH. While brief reference will be made to adult studies
on SCH, it is important to point out why one cannot
simply extrapolate adult data to children.Many children with
SCH are identified at a young age, so the elevated TSH is
often not an acquired condition due to mild autoimmune
thyroiditis, as is typically the case in adults, but likely a mild,
compensated congenital condition.
2. Why Are Thyroid Tests Ordered So
Frequently?
One key reason SCH appears to be so common in children
is that an increasing number of children undergo thyroid
testing. Thyroid tests are most helpful in the child with a
newly detected goiter or when there are more than one of the
classic symptoms of hypothyroidism or hyperthyroidism. In
practice, thyroid tests are often ordered in situations where
OH is unlikely to be found, including (1) as part of a lab
evaluation for obesity, (2) in the work-up of fatigue with
no goiter and no other symptoms of hypothyroidism, (3) in
children with a family history of hypothyroidism, (4) in short
healthy children with normal growth rates, (5) in patients
about to start or patients taking psychoactive medications,
(6) in children with precocious or delayed puberty, and (7) in
girls with irregular menses. One study from Germany looked
at thyroid tests in over 1400 patients evaluated for obesity
and reported hypothyroidism in only 0.3%, indicating the
low yield in screening this population [2]. A recent study
from one insurance company in Israel found that 24% of
12–16 year old children had at least one TSH ordered over
a 5-year period, a very high proportion [3].
3. Natural History Studies of SCH in Children
(Summarized in Table 1)
Many cases of SCH in children are identified in the newborn
period due to screening for congenital hypothyroidism. A
longitudinal study from Italy followed a group of 44 infants
identified with elevated TSH on newborn screening, whose
follow-up TSH at a mean of 22 days of life was either normal
(<5mU/L; 23 infants) or mildly elevated (5–12mU/L; 21
infants) [4]. All of the 16 children who had TSH levels
<4.0mU/L at 16–44 months continued to have normal TSH
at 4.1–6.6 years and at 7.2–9.5 years. Of the 28 whose TSH
levels were in the 4–11mU/L range at 16–44 months, 1/3 had
their TSH normalized during prolonged follow-up, but 2/3
had persistent TSH elevation. Twenty of 28 were treated with
l-thyroxine and then withdrawn from treatment 2 months
before retesting; none had a TSH >10mU/L oﬀ treatment.
Thyroid ultrasound revealed hypoplasia of one lobe or
thyroid hemiagenesis or goiter in half the subjects. The
authors concluded that mild TSH elevation in the newborn
period may be a marker for significant congenital anatomic
or thyroid function abnormalities and that such children are
at high risk for persistent TSH elevation. However, since
none of their subjects developed OH during follow-up of
up to 9.5 years, the practical significance of these congenital
abnormalities is not clear.
A novel approach to studying the outcome of mild TSH
elevation was taken by an Israeli group, who used a database
of 121,000 children followed by a single organization who
had a TSH done in 2002 [3]. Patients who had both a
low free T4 and TSH >10mU/L at the initial screening
or during follow-up (only 0.4%) were treated. There were
2.9% whose initial TSH was >5.5 to 10mU/L, and over the
subsequent 5 years 73.6% had the TSH normalize, in 1/4 it
remained borderline, and it rarely increased to >10 during
subsequent testing. For patients with a normal free T4 and
TSH >10mU/L who were not treated, the second TSH was
normal in 40%, decreased to the mildly elevated range in
33%, and remained >10mU/L in only 25%.
In a recent prospective follow-up study of 92 Italian
children ages 5–15 with “idiopathic” SCH (no goiter and
negative thyroid antibodies) [5], 38 patients had normal-
ization of TSH (none in the first 6 months, 16 between 6
and 12 months and 22 between 12 and 24 months). There
were 54 patients (59%) whose TSH remained elevated in
the 5–10 range, and only 11 patients had TSH increase to
>10mU/ml; in all cases it was between 10.5–15mU/L. Free
T4 levels remained normal in all patients. No lab test done at
baseline was predictive of either normalization or a further
increase in TSH.
The most common cause of acquired OH in both chil-
dren and adults is autoimmune or Hashimoto’s thyroiditis
(AIT). Moore [6] reported on 18 children (mostly age 10–
19) who had mild to significant TSH elevation (as high as
60mU/L), normal T4, positive thyroid antibodies, and in
some cases a goiter. Eleven were monitored oﬀ treatment and
7 were treated for 5–10 years and then retested after at least
1 year oﬀ treatment. In 7 patients, TSH normalized, in 10
patients it remained mildly to moderately elevated but with
a normal T4, and only a single patient had both a low T4 and
elevated TSH. Three patients in the treated group with initial
TSH in the 50–64 range had normal T4 and TSH in the 3–10
range oﬀ therapy. This small study shows that SCH due to
AIT can persist for years without progression to OH and that
patients with moderate TSH elevation may have a recovery
of thyroid function over time.
A larger study of the natural history of children with
AIT from Italy examined 160 children with positive thyroid
antibodies, ultrasonography of the thyroid compatible with
AIT, and TSH either normal or 100–200% of the upper limit
of normal (ULN) [7]. Patients were treated if their TSH
increased to >200% ULN or followed for at least 5 years. In
the 55 patients with TSH 100–200% of the ULN at the first
visit, TSH normalized in 29%, remained mildly elevated in
29%, and became elevated to >200% of the ULN in 42%.
Since treatment was started as soon as TSH exceeded 200%
of the ULN, it was not clear what proportion actually would
have developed OH with a low free T4. Although larger
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Table 1: Natural history studies of subclinical hypothyroidism in children.
Patient population N with SCH Years of f/u Outcomes Ref
Abnormal newborn screening TSH 28 7.2–9.5 years
9 with normal TSH
19 with TSH 4–10
0 with TSH >10
[4]
Children in a single health care system
screened in 2002; no known thyroid disease
3,475 Up to 5 years
73.6% with normal TSH
≈25% with TSH 5.5–10
≈2% with TSH >10
[3]
Idiopathic SCH—no antibodies, no goiter 92 2 years
38 with normal TSH
43 with TSH 5–10
11 with TSH >10 (10.5–15)
[5]
Autoimmune thyroiditis: nl T4 and TSH
5–64mU/L
18 Mean of 5.8 years
7 with normal TSH
10 with normal T4, ↑ TSH
1 with low T4, ↑ TSH
[6]
Autoimmune thyroiditis 55 At least 5 years
16 with normal TSH
16 with TSH 1-2x ULN
23 with TSH > 2x ULN
[7]
Patients with SCH maintained on low doses
of l-thyroxine
30 Mean of 3.5 years on
l-thyroxine then stopped
14 with TSH <5
12 with TSH 5–9.9
4 with TSH 10–15
[9]
Down syndrome: mean age 16.4 ± 10 years 70 2–7 years
19 with normal TSH
46 with SCH
3 with overt hypothyroidism
2 with hyperthyroidism
[10]
thyroid volume and increased thyroglobulin antibodies were
somewhat predictive of deterioration of thyroid function for
the group as a whole, no parameters predicted the course in
individual patients.
In a series of 23 children with AIT based on one positive
thyroid antibody and the typical ultrasonographic pattern
(usually a heterogeneous and hypoechogenic pattern) [8],
there were 7 euthyroid patients, 14 with SCH and 2 with
OH. Euthyroid patients had persistently normal TSH during
a median of 4.7 years of follow-up. Patients with SCH and
OH were treated with l-thyroxine for a median of 6.4 years.
After withdrawal from therapy, 10/14 children with SCH had
TSH levels very close to initial levels, 3 patients with initial
TSH 13.7 ± 3 had normalization of TSH (2.7 ± 0.7), and
only one of 14 had worsening thyroid function.
The author recently analyzed a group of 30 children
started on l-thyroxine when they had normal total or
free T4 but a mildly to moderately elevated TSH (range
of 5–40mU/L). These selected children did not require
increases in l-thyroxine dose over time (in some cases it was
decreased), and TSH remained normal on 25–50mcg/day
[9]. Seventeen of the 30 were started on treatment in the
first year of life (10 in the first 2 months), and 6 had Down
syndrome. They were treated for a mean of 3.5 years (range
0.5–8.5 years). After at least one month oﬀ treatment, most
children had slightly lower but still normal free T4 levels;
14/30 had TSH <5mU/L, 12/30 had TSH 5.0–9.9mU/L, and
4 had TSH 10–15mU/L. None had a TSH higher than the
initial level which prompted initiation of therapy, and none
developed typical hypothyroid symptoms. This study, like
the ones cited above, suggests that most children with normal
free T4 and mildly elevated TSH, many identified in the
first year of life, do not have a clinical course of progressive
thyroid failure.
4. SCH in Down Syndrome and Other
Syndromes
It has been long known that SCH is particularly common
in children with Down syndrome. Rubello et al. reported
that 32.5% of a group of 344 Italian Down syndrome
children had SCH and that thyroid antibodies were not
much more likely to be found in this group (18.7%) than
in Down syndrome patients with normal TSH (15.7%) [10].
During a mean of 3 years of follow-up of 70 patients, TSH
normalized in 27% and remained mildly elevated in 66%;
overt hypothyroidism developed in 7% and hyperthyroidism
in 4%, but only in the subset of patients who were antibody
positive (Table 1). Another study of 137 children with
Down syndrome found 4 cases of congenital hypothyroidism
(3%), 8 cases (6%) of acquired OH, and 4 cases (3%) of
hyperthyroidism [11]. All of the acquired OH children and
the hyperthyroid children had positive thyroid peroxidase
antibodies. There were an additional 53 cases (39%) with
normal T4 and mildly elevated TSH (5–13mU/L), of whom
24% had positive antibodies, compared with 13% positive
antibodies in children with TSH <5mU/L. No improvement
in growth velocity was found in the 9 patients with mild TSH
elevation who were treated with l-thyroxine. The etiology of
the high frequency of SCH in Down syndrome is unknown.
Tonacchera et al. did not find inactivating mutations of the
TSH-receptor in 12 Down syndrome children with elevated
TSH [12], and Konings et al. found no evidence for a TSH
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with reduced biological activity in serum from children with
Down syndrome compared to normal children [13].
In a study of 92 children withWilliam syndrome between
the ages of 0.2 and 17 years, none were found to have OH,
but 31.5% had SCH, with negative thyroid antibodies and
stable thyroid function over time [14]. Thyroid function has
also been evaluated in detail in a large group of 120 subjects
from infancy to age 32 with the chromosome 18 q-syndrome.
There were 12% with primary hypothyroidism and several
patients were found who fit the definition of SCH, but
the frequency of SCH in this population was not defined
[15].
5. Does SCH Cause Symptoms and
Is Treatment Beneficial?
There is an almost complete lack of pediatric randomized
controlled trial data on this subject so one is obligated to
refer to adult studies. The debate over treatment of adult
SCH has persisted for years, and review articles have been
published. In 2001, the Journal of Clinical Endocrinology
aired both sides of the debate, with one article taking the
position “Subclinical hypothyroidism is mild thyroid failure
and should be treated” [16] and the other article stating
“The treatment of subclinical hypothyroidism is seldom
necessary” [17]. In the latter article, studies were reviewed
which examined the eﬀect of treatment of SCH on improved
quality of life, blood lipid levels, or resolution of hypothyroid
symptoms. While some studies do appear to show slight
improvement in lipid levels with treatment, a rigorous
analysis indicates that for studies which included only
subjects with TSH in the 4.5–10mU/L range, no benefit was
seen. In 2005, a consensus statement was published jointly by
the American Association of Clinical Endocrinologists, the
American Thyroid Association, and The Endocrine Society
which concluded after review of the evidence and an opinion
survey of thyroid specialists that treatment of patients with
SCH with TSH levels of 4.5–10mU/L was appropriate [18].
However, in the same issue, the chairman of the panel
appointed by the 3 societies voiced disagreement with the
consensus statement [19], concluding that the only adverse
outcome of not treating adults with SCH was development
of OH at a rate of 2.6% per year in patients without thyroid
peroxidase antibodies and 4.3% per year in the presence of
thyroid antibodies, based on data from the Wickham survey
of thyroid disease in the community [20].
Since thyroid hormone is important for brain develop-
ment in young children, the eﬀect of SCH and its treatment
on cognitive development would be of interest. One report
used data from the Third National Health and Nutrition
Examination Survey (NHANES III) which included 1327
adolescents ages 13–16, of whom 1.7% (n = 22) had SCH
[21]. Curiously, the mean reading and block design scores in
the SCH children were higher than for the 1275 euthyroid
subjects, though the clinical significance is not clear. One
treatment study looked at 11 children (8 with congenital
SCH and 3 with acquired SCH) who had a battery of tests
oﬀ and on thyroid hormone replacement for an average of
91 days and no diﬀerences in neuropsychological test scores
were found [21].
Severe acquired hypothyroidism can result in slow
growth and short stature. A recent study from Brazil looked
at thyroid tests in 367 short children (average age 10.9 years)
with no defined cause. SCH was found in 46 patients or
12.5%, but there was no diﬀerence in total T4 level or height
SD score between the short children with SCH and those
with normal TSH [22]. The authors treated 20 of the 46 SCH
children SCH with l-thyroxine for 12 months; there was no
significant diﬀerence in growth velocity between the treated
and untreated SCH children, and the control short children
with normal TSH [23].
In the absence of any evidence that treatment of SCH
in children is beneficial, some clinicians take the view that
since severe untreated OH can cause developmental delay
in newborns and slowing of growth in older children, one
should err on the side of caution. This view is summarized in
a 2007 commentary [24], proposing that thyroid antibodies
and ultrasound can be performed in all children with SCH
and that “because the potential harm of early treatment
appears to be so minor and limited, it seems prudent to
err on the side of provisional diagnosis and early treatment
rather than wait until suﬃcient information is available to
determine the issue of whether to treat or not.”
6. Etiology of Subclinical Hypothyroidism
Since most recent longitudinal studies show that at about 1/3
of patients with SCH have normalization of TSH over time
whereas most of the remainder have persistent mild TSH
elevation, causes of SCHwill be considered in these 2 distinct
subgroups.
6.1. Transient SCH
(1) Random TSH Variation. TSH levels in healthy indi-
viduals tend to fluctuate during the day as well as over
time. One study compared early morning fasting and
late morning TSH levels in 100 patients. In 97, TSH
declined during the morning, by a mean of 26% [25].
If we define a TSH of >5.0mU/L as abnormal, a child
could have a TSH of 6.0mU/L on one occasion and
4.0mU/L when repeated later (particularly if done at
a diﬀerent time of day) with no real change in thyroid
status. Although one might conclude that SCH had
“resolved”, the TSH remains in the range which may
be normal for that child but mildly elevated for the
general population.
(2) Non-Thyroidal Illness. A child with an active or
recent acute illness may have a transient drop in
thyroid hormone production. During the recovery
phase, a transient increase in TSH is the normal
mechanism for restoring normal free T4 levels, and
TSH will return to normal within a short period of
time.
(3) Mild AIT Which Recovers or Improves. As noted
above [6, 8], pediatric AIT does not inevitably destroy
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the thyroid but may go into remission, allowing the
thyroid gland to recover and TSH to normalize, even
in cases where enlargement of the thyroid gland
persists.
6.2. Persistent SCH
(1) The normal TSH range is defined as range in which
95% of values in healthy people fall; thus about 2.5%
of normal individuals will have and maintain a TSH
at or slightly above the upper end of the normal
range.
(2) Mild Developmental Thyroid Abnormalities. The
study which followed children with mild TSH ele-
vation found on newborn screening [4] identified 8
of 19 children with hypoplasia of one lobe or hemia-
genesis of the thyroid. If these minor developmental
abnormalities are functionally related to the TSH
elevation, there appears to be a suﬃcient amount
of thyroid tissue to sustain normal thyroid hormone
production for many years. Whether TSH levels
would increase in such patients after the pubertal
growth spurt, when there is often an increase in
thyroid hormone requirement, is not known.
(3) Children Born Small for Gestational Age. A recent
study from Argentina of 53 children born SGA, with
mean age 5.6 ± 3.2 years, impaired catch-up growth,
and negative thyroid antibodies, found that 1/2 had
an exaggerated TSH response to thyrotropin releasing
hormone (TRH) compared to control children. Both
groups had identical mean free T4 levels but the
group with exaggerated TRH response had a mean
TSH of 6.2 (4.2–14.6) versus 3.2 (1.6–7) in the
normal TRH response group. The authors speculate
that children with intrauterine growth retardation
may develop abnormal TSH regulatory circuitry
characterized by an abnormal TSH set point without
alteration in thyroid function [26].
(4) Mild Stable Autoimmune Thyroiditis. Although it
seems more likely that AIT would over time either
resolve or cause thyroid failure, theremay be a variant
form of AIT in which the gland’s minimally impaired
ability to produce thyroid hormone remains stable
over a long period of time.
(5) Obesity. There have been several reports linking
obesity to increased TSH. The best of these, a study
of 86 patients at the Cleveland Clinic who underwent
weight reduction surgery, found that prior to surgery,
10.5% had thyroid tests consistent with SCH and
there was a strong correlation between BMI and
TSH [27]. Following weight loss surgery with a mean
decrease in BMI from 49 to 32 kg/m2, mean TSH
decreased from 4.5 to 1.9mU/L with no change
in free T4 levels. A pediatric study which looked
at multiple factors involved in SCH reported that
28.4% of 88 patients with SCH and negative thyroid
antibodies were obese or overweight [28]. While the
mechanism for obesity-related elevation of TSH has
not been elucidated, it is not surprising that when
screening obese children for thyroid disease, SCH is
found far more often than OH.
(6) Mutations in the TSH-Receptor (TSH-R). A break-
through in understanding SCH has come from
studies showing that some children with SCH have
defined mutations in the TSH-receptor (TSH-R)
gene. A recent study from Japan examined 102
children with permanent TSH elevation found on
newborn screening; 3/70 with TSH >10mU/L had
mutations in each of the 2 TSH-R genes, and 3/32
with TSH 5–10mU/L had single mutations in the
TSH-R gene [29]. In the study from Italy cited above
[25], of their 88 pediatric SCH subjects, 10 had
mutations where an eﬀect on TSH-receptor signaling
had been found in previous studies; most of the
TSH-R mutations is this study were found in one
allele. In the most recent report on the subject, TSH-
R mutations were found in 11 of 39 or 28% of a
group of 39 children with nonautoimmune SCH.
Three of the subjects had hypoplastic glands on
ultrasound [30]. These observations provide a logical
explanation as to why many of children with SCH
are identified in the newborn period and why their
TSH remains so stable over many years of follow-
up. If the TSH-receptor has a reduced ability to bind
or be activated by TSH, it may take 2–4 times the
normal amount of TSH to optimally activate the
TSH-receptors (i.e., mild TSH resistance).
7. Conclusions from Literature Review
The weight of evidence from the above studies points to most
cases of persistent SCH representing stable alterations of the
child’s pituitary-thyroid axis such that normal free T4 levels
are maintained over a period of many years in the presence
of slightly elevated TSH levels. It is notable how infrequently
SCH progress to OH over time, even in those children with
features suggestive of AIT where such progression should be
common. While only a minority of SCH patients may have
mutations of the TSH-R, that situation provides the clearest
example for what may prove to be the underlying physiology
of most cases of persistent pediatric SCH: euthyroidism with
(for a variety of reasons both congenital and acquired) a mild
elevation of TSH.
8. Suggestions for Management of SCH
While there is a need for placebo-controlled treatment trials
in SCH children looking at neurocognitive functioning and
lipid levels, given the negative or inconclusive outcomes
of such studies in adults, where it is far easier to study
large numbers of patients, it does not seem likely that such
studies in children would provide strong evidence in favor
of treatment. Thus with the information currently available,
the following suggestions for how SCH could bemanaged are
proposed.
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(1) When screening for thyroid disease, primary care
physicians should be advised to only order a free
T4 and TSH. T3 uptake, T3, and free T3 add cost
and are often abnormal in the absence of thyroid
disease. There is controversy as to how helpful
thyroid antibodies are as a screening test, since they
are often positive in normal children, though less
often than in adults. For example, in the NHANES
III study in the US, 13% of the total population
had thyroid peroxidase, and 11.5% had thyroglobulin
antibodies; for the subset of 12–19 year olds (children
under 12 were not included), the figures were 4.8%
and 6.3%, with higher rates of positivity in females
than in males [31].
(2) A normal total or free T4 with a TSH of 5–10mU/L
is generally not the cause of whatever symptoms
prompted the ordering of the thyroid tests in the first
place, since it is the decrease in free T4 not increased
TSH, which results in hypothyroid symptoms. Dif-
ferent patients have diﬀerent set points for free T4, so
that a child with a free T4 of 1.1 ng/dL (0.9–1.5) and
TSH 2.0mU/L is euthyroid, while another patient
with free T4 1.1 ng/dL and TSH 30mU/L presumably
once had a higher free T4, now has a failing thyroid
gland and needs treatment. Nonetheless, few patients
experience classic symptoms of hypothyroidism until
their free T4 falls below the population normal range.
(3) If there is a goiter or the TSH is >10mU/L, treatment
is more likely to be indicated, as the odds of
underlying thyroid disease are greater. While there
are no pediatric studies which make this point clear,
one study of adults older than age 55 calculated the
progression of SCH to OH as 1.76 cases per 100
patient yearly with an initial TSH of 5.0–9.9, 19.67 for
an initial TSH 10–14.9, and 73.47 for an initial TSH
15.0–19.9 [32]. In the same study, having a goiter
increased the odds of progression to OH by a factor
of 2.47.
(4) If there is no goiter and TSH is<10, repeat free T4 and
TSH is suggested in 6–12 months. Repeating the tests
within a month, as is often done, usually results in a
TSH similar to the initial one and provides no new
information. By waiting 6–12 months, one allows
time for either normalization of TSH or progression
to OH. It may be more helpful to measure thyroid
antibodies with the second free T4 and TSH than as a
screening test. If they are negative, it would provide
reassurance that one is likely not dealing with AIT
and would decrease the need for subsequent testing,
while strongly positive antibody levels would signal
the need for closer monitoring of thyroid tests.
(5) Further studies are needed to answer the question
of how long one needs to monitor TSH in a child
with SCH to make sure he or she has not progressed
to OH. It is proposed that TSH be rechecked
periodically for 2 years (longer if there is a goiter or
strongly positive antibodies). If the TSH remains in
the 5–10mU/L range, the child could be considered
to have a stable mild TSH elevation and not require
repeat testing unless a goiter appears, or there are new
symptoms suggestive of OH.
(6) Since a child with TSH 5–10mU/L, no goiter, and
negative antibodies is unlikely to progress to OH,
it is diﬃcult to justify treatment. Even though an
occasional child in this group will develop symp-
tomatic OH during follow-up, long-term outcome
is not improved by “catching it early.” In the less
common situation when free T4 is normal but
TSH is 10–15, progression to OH is more likely,
particularly if there is evidence of AIT. Treating such
patients seems reasonable, but periodic monitoring
oﬀ therapy should also be an option.
(7) For children in the first 2 years of life with a clearly
normal free T4 but mild persistent TSH elevation, the
risk of developmental delay by withholding treatment
should be very small, as AIT and progression to OH
at this age appear to be rare. If a decision is made to
treat and the TSH remains <5mU/L, a one-month
trial oﬀ l-thyroxine for reevaluation of thyroid status
around the age of 3 years is suggested.
9. Conclusion
SCH is a very common finding in children, and several
etiologies have been identified. Natural history studies
indicate that over time, the majority of elevated TSH levels
either revert to normal or remain mildly elevated. Children
with persistent TSH elevation may be viewed as normal
variants in which there is a stable equilibrium allowing
normal thyroid hormone production in the presence of mild
TSH elevation. The number of cases in which progression to
OH has been small in all studies was reviewed, so occasional
monitoring rather than immediate treatment may be the
preferred strategy. Studies on children with mutations of
the TSH-receptor suggest that some SCH patients without
features of AIT may have increased TSH due to thyroid
resistance to the eﬀect of TSH. Preliminary studies suggest
that treatment of SCH has no beneficial eﬀect on growth,
but additional studies are needed to determine if there are
any measurable benefits (aside from the lowering of TSH) to





TSH: Thyroid stimulating hormone
TSH-R: TSH-receptor.
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